316 related articles for article (PubMed ID: 34125415)
1. Current Approaches to Philadelphia Chromosome-Positive B-Cell Lineage Acute Lymphoblastic Leukemia: Role of Tyrosine Kinase Inhibitor and Stem Cell Transplant.
Kim K; Jabbour E; Short NJ; Kebriaei P; Kantarjian H; Ravandi F
Curr Oncol Rep; 2021 Jun; 23(8):95. PubMed ID: 34125415
[TBL] [Abstract][Full Text] [Related]
2. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
[TBL] [Abstract][Full Text] [Related]
3. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
[TBL] [Abstract][Full Text] [Related]
4. Treatment Selection for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors.
Ma Y; Zhang Q; Kong P; Xiong J; Zhang X; Zhang C
Chemotherapy; 2019; 64(2):81-93. PubMed ID: 31390613
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Abou Dalle I; Jabbour E; Short NJ; Ravandi F
Curr Treat Options Oncol; 2019 Jan; 20(1):4. PubMed ID: 30675645
[TBL] [Abstract][Full Text] [Related]
6. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel S; Czyz A; Ottmann O; Baron F; Brissot E; Ciceri F; Cornelissen JJ; Esteve J; Gorin NC; Savani B; Schmid C; Mohty M; Nagler A
Cancer; 2016 Oct; 122(19):2941-51. PubMed ID: 27309127
[TBL] [Abstract][Full Text] [Related]
7. How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?
Wieduwilt MJ
Best Pract Res Clin Haematol; 2017 Sep; 30(3):201-211. PubMed ID: 29050693
[TBL] [Abstract][Full Text] [Related]
8. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions.
Samra B; Jabbour E; Ravandi F; Kantarjian H; Short NJ
J Hematol Oncol; 2020 Jun; 13(1):70. PubMed ID: 32503572
[TBL] [Abstract][Full Text] [Related]
9. The emerging use of chemotherapy-free regimens in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sawyers JD; Jammal NJ; Short NJ; Kantarjian H; Jabbour EJ
Clin Adv Hematol Oncol; 2023 Feb; 21(2):68-75. PubMed ID: 36780472
[TBL] [Abstract][Full Text] [Related]
10. [Current management of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Onizuka M
Rinsho Ketsueki; 2018; 59(10):2028-2035. PubMed ID: 30305505
[TBL] [Abstract][Full Text] [Related]
11. SOHO State of the Art Updates and Next Questions: Update on the Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Haddad FG; Jabbour E; Short NJ; Jain N; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):271-276. PubMed ID: 38185587
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
Brissot E; Labopin M; Beckers MM; Socié G; Rambaldi A; Volin L; Finke J; Lenhoff S; Kröger N; Ossenkoppele GJ; Craddock CF; Yakoub-Agha I; Gürman G; Russell NH; Aljurf M; Potter MN; Nagler A; Ottmann O; Cornelissen JJ; Esteve J; Mohty M
Haematologica; 2015 Mar; 100(3):392-9. PubMed ID: 25527562
[TBL] [Abstract][Full Text] [Related]
13. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Wang J; Jiang Q; Xu LP; Zhang XH; Chen H; Qin YZ; Ruan GR; Jiang H; Jia JS; Zhao T; Liu KY; Jiang B; Huang XJ
Biol Blood Marrow Transplant; 2018 Apr; 24(4):741-750. PubMed ID: 29247779
[TBL] [Abstract][Full Text] [Related]
15. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
16. Curing Ph+ ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant.
Fielding AK
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):24-29. PubMed ID: 31808885
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib.
Tachibana T; Tanaka M; Noguchi Y; Najima Y; Sadato D; Harada Y; Tamai Y; Doki N; Nakajima H
Hematology; 2024 Dec; 29(1):2360843. PubMed ID: 38828928
[TBL] [Abstract][Full Text] [Related]
18. Ph+ ALL in 2022: is there an optimal approach?
Wieduwilt MJ
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):206-212. PubMed ID: 36485090
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic or preemptive tyrosine kinase inhibitor therapy after allogeneic hematopoietic cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Nakasone H
Int J Hematol; 2023 Aug; 118(2):183-192. PubMed ID: 36807259
[TBL] [Abstract][Full Text] [Related]
20. New Treatment Strategies for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Saini L; Brandwein J
Curr Hematol Malig Rep; 2017 Apr; 12(2):136-142. PubMed ID: 28243848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
